5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: A retrospective analysis

Bone Marrow Transplantation

Volumn 45, Issue 5, 2010, Pages 872-876

  Czibere, A ^a   Bruns, I ^a   Kroger N ^b   Platzbecker, U ^c   Lind, J ^a   Zohren, F ^a   Fenk, R ^a   Germing, U ^a   Schroder T ^a   Graf T ^a   Haas, R ^a   Kobbe, G ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

5 Azacytidine; Allo SCT; AML; MDS; Relapse

Indexed keywords

AZACITIDINE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; DRUG FATALITY; FEMALE; HUMAN; LEUKEMIA RELAPSE; LEUKOCYTE COUNT; LYMPHOCYTE TRANSFUSION; MALE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT RESPONSE;

ADULT; AGED; AZACITIDINE; FEMALE; GRAFT VS HOST DISEASE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS;

EID: 77952419308     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.266     Document Type: Article

References (23)

1. Arellano ML, Langston A, Winton E, Flowers CR, Waller EK. Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience. Biol Blood Marrow Transplant 2007;13:116-123.
2. Schmid C, Labopin M, Nagler A, Bornhauser M, Finke J, Fassas A et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT acute leukemia working party. J Clin Oncol 2007;25:4938-4945.
3. Schmid C, Schleuning M, Schwerdtfeger R, Hertenstein B, Mischak-Weissinger E, Bunjes D et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 2006;108:1092-1099.
4. Platzbecker U, Binder M, Schmid C, Rutt C, Ehninger G, Bornhauser M. Second donation of hematopoietic stem cells from unrelated donors for patients with relapse or graft failure after allogeneic transplantation. Haematologica 2008;93:1276-1278.
5. Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb HJ. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005;23:5675-5687.
6. Creusot F, Acs G, Christman JK. Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2'-deoxycytidine. J Biol Chem 1982;257:2041-2048.
7. Sorm F, Piskala A, Cihak A, Vesely J. 5-Azacytidine, a new, highly effective cancerostatic. Experientia 1964;20:202-203.
8. Graef T, Kuendgen A, Fenk R, Zohren F, Haas R, Kobbe G. Successful treatment of relapsed AML after allogeneic stem cell transplantation with azacitidine. Leuk Res 2007;31:257-259.
9. Kuendgen A, Graf T, Zohren F, Hildebrandt B, Hunerliturkoglu A, Gattermann N et al. Induction of complete remission in a patient with acute myeloid leukemia refractory to highdose chemotherapy through treatment with 5-azacytidine. Leuk Res 2007;31:407-409.
10. Saiki JH, McCredie KB, Vietti TJ, Hewlett JS, Morrison FS, Costanzi JJ et al. 5-azacytidine in acute leukemia. Cancer 1978;42:2111-2114.
11. Sudan N, Rossetti JM, Shadduck RK, Latsko J, Lech JA, Kaplan RB et al. Treatment of acute myelogenous leukemia with outpatient azacitidine. Cancer 2006;107:1839-1843.
12. Collins Jr RH, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997;15:433-444.
13. Depil S, Deconinck E, Milpied N, Sutton L, Witz F, Jouet JP et al. Donor lymphocyte infusion to treat relapse after allogeneic bone marrow transplantation for myelodysplastic syndrome. Bone Marrow Transplant 2004;33:531-534.
14. Porter DL, Collins Jr RH, Hardy C, Kernan NA, Drobyski WR, Giralt S et al. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood 2000;95:1214-1221.
15. Takami A, Okumura H, Yamazaki H, Kami M, Kim SW, Asakura H et al. Prospective trial of high-dose chemotherapy followed by infusions of peripheral blood stem cells and doseescalated donor lymphocytes for relapsed leukemia after allogeneic stem cell transplantation. Int J Hematol 2005;82:449-455.
16. Platzbecker U, Radke J, Kiani A, Bonin M, Goekkurt E, Oelschlagel U et al. 5-azacitidine treatment of imminent relapse defined by decreasing donor CD34+ progenitor subset chimerism in patients with CD34+ high-risk myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) after allogeneic stem cell transplantation. Blood 2008;112(abstract. 2143).
17. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002;20:2429-2440. (Pubitemid 34525728)
18. Siegert W, Beyer J, Kingreen D, Blasczyk R, Baurmann H, Schwella N et al. Treatment of relapse after allogeneic bone marrow transplantation with unmanipulated G-CSF-mobilized peripheral blood stem cell preparation. Bone Marrow Transplant 1998;22:579-583.
19. Santourlidis S, Trompeter HI, Weinhold S, Eisermann B, Meyer KL, Wernet P et al. Crucial role of DNA methylation in determination of clonally distributed killer cell Ig-like receptor expression patterns in NK cells. J Immunol 2002;169:4253-4261.
20. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995;86:2041-2050.
21. Kolb HJ, Schmid C, Barrett AJ, Schendel DJ. Graft-versusleukemia reactions in allogeneic chimeras. Blood 2004;103:767-776.
22. Oh H, Loberiza Jr FR, Zhang MJ, Ringden O, Akiyama H, Asai T et al. Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations. Blood 2005;105:1408-1416.
23. Porter DL, Roth MS, McGarigle C, Ferrara JL, Antin JH. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 1994;330:100-106.